INVEX Therapeutics Ltd - Asset Resilience Ratio

Latest as of June 2026: 61.52%

INVEX Therapeutics Ltd (IXC) has an Asset Resilience Ratio of 61.52% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See INVEX Therapeutics Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$2.50 Million

≈ $1.77 Million USD Cash + Short-term Investments

Total Assets

AU$4.06 Million

≈ $2.88 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2026–2026)

This chart shows how INVEX Therapeutics Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see INVEX Therapeutics Ltd asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down INVEX Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read IXC total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$2.50 Million	61.52%
Total Liquid Assets	AU$2.50 Million	61.52%

Asset Resilience Insights

Very High Liquidity: INVEX Therapeutics Ltd maintains exceptional liquid asset reserves at 61.52% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

INVEX Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare INVEX Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for INVEX Therapeutics Ltd (2026–2026)

The table below shows the annual Asset Resilience Ratio data for INVEX Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2026-06-30	61.52%	AU$2.50 Million ≈ $1.77 Million	AU$4.06 Million ≈ $2.88 Million	--

pp = percentage points

About INVEX Therapeutics Ltd

AU:IXC Australia Biotechnology

Market Cap

$5.58 Million

AU$7.89 Million AUD

Market Cap Rank

#28475 Global

#1497 in Australia

Share Price

AU$0.11

Change (1 day)

-8.70%

52-Week Range

AU$0.09 - AU$0.16

All Time High

AU$1.67